Trial intelligence / Profile preview

Six-week double-blind placebo-controlled Phase III trial of oral ziprasidone in adolescents with schizophrenia

2005-005501-28Phase 3Terminated

Sponsor
Pfizer
Start
Dec 2005
Modality
Small Molecules
Countries
1
01

Overview

Phase 3, randomised, double-blind trial in schizophrenia comparing Ziprasidone flexible-dose with Placebo (2 arms). Started Dec 2005; status: terminated.

02

Drugs

ziprasidone
03

Conditions

schizophrenia

Beyond the preview

Go deeper on 2005-005501-28.

Study design, results and competitive context are available in the Gosset platform where reported.

Study design & results

Available in the Gosset platform where reported.

Competitive context

Available in the Gosset platform where reported.

Bring the full picture into focus.

See how Gosset can support your research on 2005-005501-28.

Gosset Free

Get started with Gosset.

Enter your corporate email.

Work email preferred.

Book a call